Reply to Winston and Shepp and to Lanzafame et al

Zimmermann, Anthony E.; Braden, Gregory; Pizzoferrato, Thomas

doi:10.1086/504082

Cited by 4 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results demonstrate a small but statistically signifi cant loss of renal function in the fi rst 3.5 months after starting a TDF containing regimen. We show that boosted PI augments this effect, possibly due to inhibition of MRP2 (Zimmermann et al, 2006). Raltegravir appears to offer some protection, which has not been shown before, but may be due to competition for the OAT1 infl ux transporter (Moss et al, 2011).…”

Section: Discussionmentioning

confidence: 65%

Abstracts of the Dutch Society of Clinical Pharmacology and Biopharmacy Meeting of October 3, 2011

2013

Brit J Clinical Pharma

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 65%

Abstracts of the Dutch Society of Clinical Pharmacology and Biopharmacy Meeting of October 3, 2011

2013

Brit J Clinical Pharma

View full text Add to dashboard Cite

“…Nonetheless, this transient dip could also be real in light of some other observational data, suggesting an initial drop in CL CR on tenofovir, which does not progress with time. 5,10,11 We postulated that due to a lower BW on average, Thai patients should have a higher exposure to tenofovir and might be more likely to develop nephrotoxicity on the standard 300 mg daily dose. However, tenofovir disoproxil fumarate was well tolerated, and significant renal toxicity was not observed.…”

Section: Discussionmentioning

confidence: 99%

No change in calculated creatinine clearance after tenofovir initiation among Thai patients

Gayet-Ageron¹,

Ananworanich²,

Jupimai³

et al. 2007

Journal of Antimicrobial Chemotherapy

View full text Add to dashboard Cite

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2006

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Reply to Winston and Shepp and to Lanzafame et al

Cited by 4 publications

References 4 publications

Abstracts of the Dutch Society of Clinical Pharmacology and Biopharmacy Meeting of October 3, 2011

Abstracts of the Dutch Society of Clinical Pharmacology and Biopharmacy Meeting of October 3, 2011

No change in calculated creatinine clearance after tenofovir initiation among Thai patients

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About